

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

1-21. (canceled)

22. (currently amended) A pharmaceutical composition comprising a solution which comprises:

- (a) ~~(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane~~ (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) or a combination of ritonavir and another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an amount of from 1% to 50% by weight of said solution;
- (b) a pharmaceutically acceptable medium and/or long chain fatty acid, or a mixture of pharmaceutically acceptable medium and/or long chain fatty acids, in an amount of from 30% to 75% by weight of said solution;
- (c) ethanol or propylene glycol in an amount of from 1% to 15% by weight of said solution;
- (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and, optionally,
- (e) a pharmaceutically acceptable surfactant.


23. (previously presented) The composition according to claim 22, wherein said solution comprises ritonavir and said another HIV protease inhibiting compound.

24. (previously presented) The composition according to claim 23, wherein said another HIV protease inhibiting compound is (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimidin-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane (ABT-378).


25. (previously presented) The composition according to claim 23, wherein said another HIV protease inhibiting compound is a compound selected from the group consisting of:

- (1) (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane,
- (2) N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir ),
- (3) N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginy]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir ),
- (4) 5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide,
- (5) 1 -Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide,
- (6) 5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide,
- (7) [1S-[1R-(R-),2S\*]]-N<sup>1</sup> [3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinoliny]carbonyl)amino]-butanediamide,


(8)




(9)




(10)




(11)




(12)



(13)




(14)



, and

(15)



(tipranavir);

or a pharmaceutically acceptable salt thereof.

26. (previously presented) The composition according to claim 22, wherein said surfactant is in an amount of from 2% to 20% by weight of said solution.

27. (previously presented) The composition according to claim 22, wherein said solution comprises ritonavir or a combination of ritonavir and said another HIV protease inhibiting compound, or pharmaceutically acceptable salts thereof, in an amount of from 10 to 40% by weight of said solution.

28. (previously presented) The composition according to claim 22, wherein said solution comprises a pharmaceutically acceptable organic solvent in an amount of from 50% to 75% by weight of said solution, and said solvent includes:

- (a) a pharmaceutically acceptable medium and/or long chain fatty acid, or a mixture of pharmaceutically acceptable medium and/or long chain fatty acids, in an amount of from 30% to 75% by weight of said solution; and
- (c) ethanol or propylene glycol in an amount of from 1% to 15% by weight of said solution.

29. (previously presented) The composition of claim 22, wherein said solution comprises water in an amount of from 0.4% to 1.5% by weight of said solution.

30. (previously presented) The composition according to claim 22, wherein said solution comprises oleic acid in an amount of from 30% to 75% by weight of said solution.

31. (previously presented) The composition according to claim 22, wherein said surfactant is polyoxyl 35 castor oil.

32. (previously presented) The composition according to claim 22, wherein said solution comprises:

- (a) ritonavir in an amount from 1% to 30% by weight of said solution;
- (b) a pharmaceutically acceptable medium and/or long chain fatty acid in an amount of from 30% to 75% by weight of said solution;
- (c) ethanol in an amount of from 1% to 15% by weight of said solution;
- (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and
- (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

33. (currently amended) The composition compound of claim 22, wherein said solution comprises:

- (a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of from 1% to 45% by weight of said solution;
- (b) a pharmaceutically acceptable medium and/or long chain fatty acid in an amount of from 30% to 75% by weight of said solution;
- (c) propylene glycol in an amount of from 1% to 15% by weight of said solution;
- (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and
- (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

34. (previously presented) The composition according to claim 22, wherein said solution comprises:

- (a) ritonavir in an amount from 1% to 30% by weight of said solution;
- (b) oleic acid in an amount of from 30% to 75% by weight of said solution;
- (c) ethanol in an amount of from 1% to 15% by weight of said solution;
- (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and
- (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

35. (previously presented) The composition according to claim 34, wherein said solution comprises:

- (a) ethanol in an amount of from 3% to 12% by weight of said solution; and
- (b) polyoxyl 35 castor oil in an amount of from 2.5% to 10% by weight of said solution.

36. (currently amended) The composition compound of claim 22, wherein said solution comprises:

- (a) ritonavir in an amount of 10% by weight of said solution;
- (b) oleic acid in an amount of from 70% to 75% by weight of said solution;
- (c) ethanol in an amount of from 3% to 12% by weight of said solution;
- (d) water in an amount of from 0.4% to 1.5% by weight of said solution; and
- (e) polyoxyl 35 castor oil in an amount of 6% by weight of said solution.

37. (currently amended) The composition compound of claim 22, wherein said solution comprises:

- (a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of from 1% to 45% by weight of said solution;
- (b) oleic acid in an amount of from 30% to 75% by weight of said solution;
- (c) propylene glycol in an amount of from 1% to 8% by weight of said solution;
- (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and
- (e) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution.

38. (currently amended) The composition compound of claim 22, wherein said solution comprises:

- (a) a combination of ritonavir and (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydropyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of 10% by weight of said solution;
- (b) oleic acid in an amount of from 70% to 75% by weight of said solution;
- (c) propylene glycol in an amount of from 1% to 15% by weight of said solution;
- (d) water in an amount of from 0.4% to 1.5% by weight of said solution; and
- (e) polyoxyl 35 castor oil in an amount of 6% by weight of said solution.

39. (previously presented) The composition according to claim 22, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

40. (previously presented) The composition according to claim 24, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

41. (previously presented) The composition according to claim 30, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

42. (previously presented) The composition according to claim 32, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

43. (previously presented) The composition according to claim 33, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

44. (previously presented) The composition according to claim 34, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

45. (previously presented) The composition according to claim 36, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

46. (previously presented) The composition according to claim 37, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.

47. (previously presented) The composition according to claim 38, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution.